Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a patented platform for the development of molecular diagnostics tests, has acquired Idaho Molecular Inc. and Advanced Conceptions Inc.
The deal provides CD with all existing and future assets and IP related to CD’s upcoming at-home/point-of-care diagnostic service. The deal was made in order to streamline the commercialization of the Eikon platform and YourTest PCR device. Co-Diagnostics plans to expand its suite of Eikon to include respiratory and infections diseases while using the firm’s patented CoPrimer Technology.
“We are pleased to announce that this important acquisition is complete, and for the value it brings to the Company as we take this step towards the next phase of our growth focused on making this next-generation healthcare solution available worldwide,” added Dwight Egan, CEO of Co-Diagnostics. “We look forward to continuing to develop and iterate new, groundbreaking products on the Eikon platform.”